India’s Life Sciences Sector at a Crossroads: Can It Scale Innovation for the Global Market?

Executive Summary

India’s life sciences sector has entered a critical phase, marked by a surge in innovation activity over the past decade. Patent filings have increased more than fourfold since 2016, the innovation pipeline has expanded by 1.5 times, and the number of biotech startups has grown by 1.6 times. Private capital directed at healthcare innovation has also risen sharply, reaching $731 million in fiscal year 2026—a 2.1-fold increase over five years. Yet a new joint report from Boston Consulting Group (BCG) and HealthKois warns that these gains remain “early and uneven,” with significant structural obstacles limiting the country’s ability to translate breakthroughs into scalable, globally competitive products.

Background

The report, titled India Pharma and Life Sciences Innovation Opportunity, assesses the nation’s trajectory from a low-cost generics manufacturer toward an innovation-driven life sciences economy. Over the past decade, India has produced 11 novel drug assets, including first-in-class new chemical entities, indigenous CAR-T therapies, and AI-discovered molecules. Notable examples include Wockhardt’s Zaynich (cefepime/zidebactam), an intravenous antibiotic that received FDA approval in June 2026 for complicated urinary tract infections, and Pandorum Technologies’ $18 million Series B raise in February 2026 for exosome-based regenerative therapies.

Main Analysis

Structural Gaps Persist

Despite these achievements, the report identifies several critical weaknesses:

Public Funding: Maximum grant sizes for early-stage research are around $52,000, compared to $2–3 million in the United States and the European Union.
Venture Capital: Indian VC firms exhibit low risk appetite for biotech investments, preferring later-stage or less capital-intensive sectors.
Clinical Trial Delays: Approval times average 90 days, versus roughly 30 days in the U.S., slowing the path to market.
Supply Chain Dependency: High reliance on imported research-grade raw materials and reagents, especially for advanced modalities like gene therapy, leads to lead times of 30–45 days.

Innovation Momentum Concentrated in Late-Stage Translation

Most of India’s innovation activity remains concentrated in late-stage translation and formulation, rather than in early-stage discovery and basic research. The report notes that while India-origin science is increasingly licensed by global pharmaceutical majors, the ecosystem lacks the depth of fundamental research needed to sustain a pipeline of novel mechanisms.

International Impact

Global Pharmaceutical Supply Chains

India’s ability to scale innovation has direct implications for global drug supply chains. As multinational companies seek to diversify manufacturing and R&D beyond China, India’s potential as a high-value innovation partner grows. However, if structural gaps are not addressed, the country risks remaining a low-cost supplier of generics and active pharmaceutical ingredients (APIs) rather than becoming a source of novel therapies.

Investment and Capital Flows

International investors and pharmaceutical firms are watching India’s life sciences evolution closely. The report suggests that building “India’s first generation of specialist biotech capital” is essential to attract deeper foreign investment. Currently, global biotech funds often bypass India due to perceived regulatory and execution risks. Closing these gaps could unlock significant cross-border investment.

Access to Affordable Therapeutics

India’s success in scaling innovation could lower costs for breakthrough therapies worldwide. Indigenous CAR-T therapies, for example, have treated patients at a fraction of the cost of U.S.-approved products. If scaled, such innovations could reshape global pricing dynamics and expand access in emerging markets.

Strategic Perspectives

Policy Priorities

The report recommends several policy interventions: fast-track regulatory pathways for novel therapies, increased public research funding, and incentives for academia-industry partnerships. The Indian government’s Production Linked Incentive (PLI) scheme for pharmaceuticals could be expanded to include innovation-stage R&D.

Business Implications

For multinational corporations, India represents both a opportunity and a risk. Joint ventures with Indian biotech firms could provide access to low-cost development platforms, but partners must navigate regulatory delays and supply chain vulnerabilities. Conversely, Indian firms that overcome these barriers could become competitive in global markets for complex generics and biologics.

Geopolitical Dynamics

India’s life sciences push is part of a broader trend of technological sovereignty and supply chain resilience. As the U.S. and Europe seek alternatives to Chinese APIs, India’s innovation upgrade could strengthen its strategic position in global health security. However, dependence on imported reagents, many from China, remains a vulnerability.

Future Outlook (2026–2036)

Over the next 3–10 years, several developments could shape India’s life sciences trajectory:

Specialist Biotech Capital: The emergence of dedicated biotech-focused venture funds, possibly with government co-investment, could fuel early-stage research.
Regulatory Streamlining: Adoption of FDA-like expedited pathways, such as breakthrough therapy designation, could reduce clinical trial timelines.
Domestic Supply Chains: Public-private initiatives to produce research-grade raw materials indigenously could cut lead times and enhance resilience.
Talent Development: Bridging the quality gap in R&D talent through specialized training programs and global collaborations is critical.

If these measures are implemented, India could produce 20–30 novel drug assets by 2035 and become a top-five global hub for biotech innovation. Without them, the sector may remain a promising but unfulfilled opportunity.

Conclusion

India’s life sciences sector stands at a genuine turning point. The country has demonstrated it can innovate, but the next decade will test whether it can scale. The structural gaps identified by the BCG-HealthKois report are not insurmountable, but they require coordinated action from government, industry, and academia. For the global community, India’s success or failure in this endeavor will have profound implications for drug affordability, supply chain diversity, and the geography of pharmaceutical innovation.